Why the study?
Does targeting the GSK-3beta pathway protect the myocardium against ischemia/reperfusion injury?
Population
Cardiomyocytes/myocardium subjected to ischemia/reperfusion injury
Design
Review
Authors
Loading...
Hypothesis-generating for GSK-3beta inhibition in ischemia/reperfusion; prospective trials needed before clinical consideration.
Does targeting the GSK-3beta pathway protect the myocardium against ischemia/reperfusion injury?
Inactivation of GSK-3beta by phosphorylation suppresses mPTP opening, presenting a promising therapeutic target for limiting myocardial ischemia/reperfusion injury.
Miura et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: